dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Harding, James J. |
dc.contributor.author | Tan, Daniel S. W. |
dc.contributor.author | Bedard, Philippe L. |
dc.contributor.author | Rodon Ahnert, Jordi |
dc.contributor.author | Doi, Toshihiko |
dc.contributor.author | Bauer, Todd |
dc.date.accessioned | 2021-04-16T14:24:14Z |
dc.date.available | 2021-04-16T14:24:14Z |
dc.date.copyright | 2018 |
dc.date.issued | 2019-04-15 |
dc.identifier.citation | Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, et al. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Invest New Drugs. 2019 Apr 15;37(2):271–81. |
dc.identifier.issn | 1573-0646 |
dc.identifier.uri | https://hdl.handle.net/11351/5870 |
dc.description | CLR457; Inhibidor Pan-PI3K; Fase I |
dc.description.sponsorship | Novartis Pharmaceuticals Corporation. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Investigational New Drugs;37(2) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tumors |
dc.subject | Inhibidors enzimàtics |
dc.subject.mesh | Protein Kinase Inhibitors |
dc.subject.mesh | Neoplasms |
dc.title | Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10637-018-0627-4 |
dc.subject.decs | inhibidores de proteínas cinasas |
dc.subject.decs | neoplasias |
dc.relation.publishversion | https://link.springer.com/article/10.1007/s10637-018-0627-4 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Harding JJ] Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Bauer TM] Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA. [Tan DSW] National Cancer Centre, Singapore, Singapore. [Bedard PL] Princess Margaret Cancer Centre, Toronto, ON, Canada. [Rodon J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Doi T] National Cancer Center East, Kashiwa, Chiba, Japan |
dc.identifier.pmid | 30073466 |
dc.identifier.wos | 000462975400007 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |